ArticleFrontiers in cellular and infection microbiology2025
Uncovering the potential of Yiqi Huoxue Jiedu formula: a promising adjunct in sepsis and septic shock management.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Yiqi Huoxue Jiedu formula protects against sepsis-associated lung injury by modulating macrophage mitophagy and mtDNA-STING signaling.Chinese medicine · 2026Article
- Shengmai Injection as adjunctive therapy in sepsis and septic shock: a retrospective cohort study.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sepsis and septic shock represent severe infectious conditions with challenging treatments. Preliminary animal studies indicate that Yiqi Huoxue Jiedu Formula (YHJF) may enhance sepsis outcomes, but no clinical trials have been conducted. This research aims to substantiate the efficacy of YHJF in treating sepsis and septic shock. Materials and methods: Mass spectrometry was used to identify the absorbed constituents of YHJF. A retrospective cohort study included sepsis patients from four sub-centers (Feb 24, 2016 - Oct 31, 2024), divided into Western treatment and YHJF plus Western care groups. Propensity score matching ensured baseline comparability. The primary outcome was 28-day mortality, with secondary outcomes including intensive care units (ICU) and hospital stay duration, mechanical ventilation and renal replacement therapy duration, fever duration, and changes in SOFA and APACHE II scores, blood procalcitonin, white blood cell count, and lactate levels after 5 days of treatment. Sepsis shock was analyzed as a subgroup. Results: YHJF absorption mainly includes Shikimates and Phenylpropanoids (33%), Terpenoids (21%), Alkaloids (14%), and Polyketides (11%). A total of 389 sepsis patients were enrolled, with 82 patients being identified as septic shock in the clinical study. The clinical results indicated that YHJF may shorten hospital stay duration, reduce ventilator duration, and improve SOFA score in sepsis. For septic shock, YHJF administration could reduce the duration of non-invasive ventilator use. Notably, YHJF has no effect on improving 28-day mortality for sepsis and septic shock. Conclusion: YHJF can reduce the SOFA score, ventilator use duration, and hospital stay length in sepsis cases and improve non-invasive ventilator use time in septic shock patients, which might attribute to the absorbed components after YHJF administration. Further high-quality trials are needed for confirmation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.